A multicenter study of recombinant human erythropoietin (epoetin α) in the management of anemia in cancer patients receiving chemotherapy

Publisher Website
Google Scholar
Abstract
Current evidence suggests that epoetin α administration is well tolerated and effective in the management of anemia of cancer and cancer chemotherapy. An open-label, multinational, non-comparative study was conducted in 215 cancer patients with anemia secondary to chemotherapy with platinum- or non-platinum-based combinations. Epoetin α was administered s.c. (150 lU/kg three times/week) for a planned period of 16 weeks. The response rate of epoetin α, defined as an increase in hemoglobin level of 2 g/dl or more from baseline, was 67%. The rate of response was not related to the chemotherapy regimen administered (platinum or non-platinum based). The percentage of patients transfused and the transfusion rate during epoetin α treatment were reduced. Transfusional need was eliminated in 64 (75%) of the 85 patients transfused before the study start, after 1 month of therapy. Quality of life, assessed using a visual analog scale, improved markedly in patients who experienced a hematological response. These patients also experienced a statistically significant (p

This publication has 0 references indexed in Scilit: